Greece · Delayed Price · Currency is EUR Lavipharm Statistics
Total Valuation
Lavipharm has a market cap or net worth of EUR 260.33 million. The enterprise value is 286.99 million.
| Market Cap | 260.33M |
| Enterprise Value | 286.99M |
Important Dates
The last earnings date was Thursday, April 23, 2026.
| Earnings Date | Apr 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Lavipharm has 169.04 million shares outstanding. The number of shares has decreased by -0.06% in one year.
| Current Share Class | 169.04M |
| Shares Outstanding | 169.04M |
| Shares Change (YoY) | -0.06% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 2.20% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 52.74.
| PE Ratio | 52.74 |
| Forward PE | n/a |
| PS Ratio | 4.16 |
| PB Ratio | 4.61 |
| P/TBV Ratio | 17.85 |
| P/FCF Ratio | 48.28 |
| P/OCF Ratio | 39.07 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.93, with an EV/FCF ratio of 53.23.
| EV / Earnings | 47.94 |
| EV / Sales | 4.59 |
| EV / EBITDA | 20.93 |
| EV / EBIT | 33.28 |
| EV / FCF | 53.23 |
Financial Position
The company has a current ratio of 1.21, with a Debt / Equity ratio of 0.58.
| Current Ratio | 1.21 |
| Quick Ratio | 0.65 |
| Debt / Equity | 0.58 |
| Debt / EBITDA | 2.39 |
| Debt / FCF | 6.08 |
| Interest Coverage | 4.68 |
Financial Efficiency
Return on equity (ROE) is 9.23% and return on invested capital (ROIC) is 6.96%.
| Return on Equity (ROE) | 9.23% |
| Return on Assets (ROA) | 4.22% |
| Return on Invested Capital (ROIC) | 6.96% |
| Return on Capital Employed (ROCE) | 10.00% |
| Weighted Average Cost of Capital (WACC) | 9.06% |
| Revenue Per Employee | 219,593 |
| Profits Per Employee | 21,004 |
| Employee Count | 282 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 1.49 |
Taxes
In the past 12 months, Lavipharm has paid 2.45 million in taxes.
| Income Tax | 2.45M |
| Effective Tax Rate | 32.69% |
Stock Price Statistics
The stock price has increased by +91.78% in the last 52 weeks. The beta is 1.00, so Lavipharm's price volatility has been similar to the market average.
| Beta (5Y) | 1.00 |
| 52-Week Price Change | +91.78% |
| 50-Day Moving Average | 1.31 |
| 200-Day Moving Average | 0.99 |
| Relative Strength Index (RSI) | 72.49 |
| Average Volume (20 Days) | 304,279 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Lavipharm had revenue of EUR 62.58 million and earned 5.99 million in profits. Earnings per share was 0.03.
| Revenue | 62.58M |
| Gross Profit | 30.31M |
| Operating Income | 8.62M |
| Pretax Income | 7.50M |
| Net Income | 5.99M |
| EBITDA | 12.92M |
| EBIT | 8.62M |
| Earnings Per Share (EPS) | 0.03 |
Balance Sheet
The company has 6.11 million in cash and 32.78 million in debt, with a net cash position of -26.67 million or -0.16 per share.
| Cash & Cash Equivalents | 6.11M |
| Total Debt | 32.78M |
| Net Cash | -26.67M |
| Net Cash Per Share | -0.16 |
| Equity (Book Value) | 56.41M |
| Book Value Per Share | 0.33 |
| Working Capital | 9.22M |
Cash Flow
In the last 12 months, operating cash flow was 6.66 million and capital expenditures -1.27 million, giving a free cash flow of 5.39 million.
| Operating Cash Flow | 6.66M |
| Capital Expenditures | -1.27M |
| Depreciation & Amortization | 4.29M |
| Net Borrowing | -1.77M |
| Free Cash Flow | 5.39M |
| FCF Per Share | 0.03 |
Margins
Gross margin is 48.42%, with operating and profit margins of 13.78% and 9.56%.
| Gross Margin | 48.42% |
| Operating Margin | 13.78% |
| Pretax Margin | 11.99% |
| Profit Margin | 9.56% |
| EBITDA Margin | 20.64% |
| EBIT Margin | 13.78% |
| FCF Margin | 8.62% |
Dividends & Yields
This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 1.30%.
| Dividend Per Share | 0.02 |
| Dividend Yield | 1.30% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 56.48% |
| Buyback Yield | 0.06% |
| Shareholder Yield | 1.36% |
| Earnings Yield | 2.30% |
| FCF Yield | 2.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 1, 2022. It was a reverse split with a ratio of 0.3333333333.
| Last Split Date | Aug 1, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.3333333333 |
Scores
Lavipharm has an Altman Z-Score of 1.7 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.7 |
| Piotroski F-Score | 8 |